HRP20120743T1 - Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja - Google Patents

Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja Download PDF

Info

Publication number
HRP20120743T1
HRP20120743T1 HRP20120743AT HRP20120743T HRP20120743T1 HR P20120743 T1 HRP20120743 T1 HR P20120743T1 HR P20120743A T HRP20120743A T HR P20120743AT HR P20120743 T HRP20120743 T HR P20120743T HR P20120743 T1 HRP20120743 T1 HR P20120743T1
Authority
HR
Croatia
Prior art keywords
disease
development
monitoring
inflammatory
assessing
Prior art date
Application number
HRP20120743AT
Other languages
English (en)
Croatian (hr)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of HRP20120743T1 publication Critical patent/HRP20120743T1/hr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HRP20120743AT 2007-10-24 2008-10-15 Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja HRP20120743T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
HRP20120743T1 true HRP20120743T1 (hr) 2012-10-31

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120743AT HRP20120743T1 (hr) 2007-10-24 2008-10-15 Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
HRP20150181TT HRP20150181T1 (hr) 2007-10-24 2015-02-16 Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20150181TT HRP20150181T1 (hr) 2007-10-24 2015-02-16 Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja

Country Status (14)

Country Link
US (1) US20100209942A1 (cg-RX-API-DMAC7.html)
EP (2) EP2201376B1 (cg-RX-API-DMAC7.html)
JP (2) JP4982610B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100059902A (cg-RX-API-DMAC7.html)
CA (1) CA2702635A1 (cg-RX-API-DMAC7.html)
CY (2) CY1113403T1 (cg-RX-API-DMAC7.html)
DK (2) DK2201376T3 (cg-RX-API-DMAC7.html)
ES (2) ES2532361T3 (cg-RX-API-DMAC7.html)
FI (1) FI20070795A0 (cg-RX-API-DMAC7.html)
HR (2) HRP20120743T1 (cg-RX-API-DMAC7.html)
PL (2) PL2503338T3 (cg-RX-API-DMAC7.html)
PT (2) PT2201376E (cg-RX-API-DMAC7.html)
SI (2) SI2201376T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5781767B2 (ja) 2008-01-18 2015-09-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 体液中における疾患または状態のシグネチャーを検出する方法
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
US20130210647A1 (en) 2010-07-23 2013-08-15 President And Fellows Of Harvard College Methods of Detecting Cardiovascular Diseases or Conditions
US20120040846A1 (en) 2010-07-23 2012-02-16 President And Fellows Of Harvard College Methods of Detecting Diseases or Conditions Using Phagocytic Cells
EP2861765B1 (en) 2012-06-15 2019-01-23 Progenity, Inc. Methods of detecting diseases or conditions
CA2876711A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN105164535B (zh) 2013-02-14 2018-04-10 法龙药品公司 测定急性呼吸窘迫综合征(ards)相关生物标志物的方法、监测患者的ards的发展和治疗的方法
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
EP3191846A4 (en) 2014-09-11 2018-06-13 Harry Stylli Methods of detecting prostate cancer
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー. ランドリ,ドナルド 抗体触媒反応の調節による有機化合物の検出
AU7310496A (en) 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
AU2002252460A1 (en) * 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
DE602004027797D1 (de) * 2003-03-28 2010-08-05 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73
US7772192B2 (en) * 2003-06-03 2010-08-10 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CA2657576C (en) * 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
PT2201376E (pt) 2012-08-20
ES2389751T3 (es) 2012-10-31
CY1116089T1 (el) 2017-02-08
KR20160029869A (ko) 2016-03-15
EP2201376A1 (en) 2010-06-30
JP4982610B2 (ja) 2012-07-25
CA2702635A1 (en) 2009-04-30
JP2011501176A (ja) 2011-01-06
ES2532361T3 (es) 2015-03-26
US20100209942A1 (en) 2010-08-19
FI20070795A0 (fi) 2007-10-24
EP2503338A2 (en) 2012-09-26
EP2201376B1 (en) 2012-08-08
JP5619810B2 (ja) 2014-11-05
EP2201376A4 (en) 2011-03-23
DK2201376T3 (da) 2012-10-15
EP2503338A3 (en) 2013-03-13
EP2503338B1 (en) 2014-12-24
KR20100059902A (ko) 2010-06-04
DK2503338T3 (en) 2015-03-09
PL2201376T3 (pl) 2013-01-31
SI2503338T1 (sl) 2015-06-30
SI2201376T1 (sl) 2012-09-28
PL2503338T3 (pl) 2015-06-30
WO2009053523A1 (en) 2009-04-30
JP2012159514A (ja) 2012-08-23
CY1113403T1 (el) 2016-06-22
PT2503338E (pt) 2015-03-05
HRP20150181T1 (hr) 2015-06-19

Similar Documents

Publication Publication Date Title
HRP20120743T1 (hr) Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
Lopes et al. Acute kidney injury in HCT: an update
JP2011501176A5 (cg-RX-API-DMAC7.html)
WO2011142827A3 (en) Diagnostic markers for neuropsychiatric disease
BR112015018213A8 (pt) métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico".
Wang et al. Risk factors for mortality in patients with septic acute kidney injury in intensive care units in Beijing, China: a multicenter prospective observational study
JP2009524829A5 (cg-RX-API-DMAC7.html)
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
EA202091766A1 (ru) Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
EA201290627A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
JP2010502177A5 (cg-RX-API-DMAC7.html)
JP2016505506A5 (cg-RX-API-DMAC7.html)
JP2015523364A5 (cg-RX-API-DMAC7.html)
WO2018236134A3 (en) METHOD AND KIT FOR THE DIAGNOSIS OF MUSCLE WEAK RELATED DISEASES USING A BLOOD BIOMARKER
JP2010502940A5 (cg-RX-API-DMAC7.html)
JP2013526863A5 (cg-RX-API-DMAC7.html)
Bagautdinova et al. Clinical polymorphism of the disease caused by Borrelia miyamotoi
Kumar et al. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project in New Delhi, India
JP2010502179A5 (cg-RX-API-DMAC7.html)
Ryu et al. Clinical features of ischemic colitis: a comparision with colonoscopic findings
Gibson et al. Thirty-year trends in incidence and age-distribution of prostate cancer in Kingston and St Andrew, Jamaica, 1978-2007
JP2012524884A5 (cg-RX-API-DMAC7.html)
Knightly et al. D41 COPD: BIOMARKERS IN STABLE DISEASE AND EXACERBATIONS: Urinary Biomarkers Implicate Proteinase Activity In Acute Exacerbations Of Chronic Obstructive Pulmonary Disease (COPD)